Does TOFACITINIB Cause Bladder transitional cell carcinoma? 6 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Bladder transitional cell carcinoma have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.0% of all adverse event reports for TOFACITINIB.
6
Reports of Bladder transitional cell carcinoma with TOFACITINIB
0.0%
of all TOFACITINIB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From TOFACITINIB?
Of the 6 reports, 6 (100.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which TOFACITINIB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN